RedHill Biopharma gets 180-day Nasdaq extension

RedHill Biopharma Ltd. received Nasdaq’s notice on October 6, 2026, granting an additional 180 calendar days, through April 5, 2027, to regain compliance with the $1.00 per-share minimum bid-price requirement.

Rhea-AI Filing Summary

RedHill Biopharma Ltd. received Nasdaq’s notice on October 6, 2026, granting an additional 180 calendar days, through April 5, 2027, to regain compliance with the $1.00 per-share minimum bid-price requirement. The earlier compliance period ran through October 5, 2026, following Nasdaq’s April 8, 2026 notice that the ADS closing bid had been below $1.00 for 30 consecutive business days.

The extension has no immediate effect on the listing or trading of RedHill’s ADSs, which continue to trade on The Nasdaq Capital Market under RDHL. Nasdaq will confirm compliance if, before April 5, 2027, the ADS closing bid is at least $1.00 per share for a minimum of 10 consecutive business days. RedHill meets the continued-listing requirement for market value of publicly held shares and all other applicable initial-listing requirements except the minimum bid requirement.

Key Figures

Additional compliance period: 180 calendar days Minimum bid-price requirement: $1.00 per share Compliance confirmation period: 10 consecutive business days +3 more

6 metrics

Additional compliance period 180 calendar days Granted through April 5, 2027

Minimum bid-price requirement $1.00 per share Nasdaq Listing Rule 5550(a)(2)

Compliance confirmation period 10 consecutive business days Closing bid must be at least $1.00 per share before April 5, 2027

Prior below-threshold period 30 consecutive business days ADS closing bid was below the minimum requirement

ADS representation 10,000 ordinary shares per ADS Each American Depositary Share represents this number of ordinary shares

Additional compliance deadline April 5, 2027 Deadline to regain compliance with Nasdaq’s minimum bid-price requirement

Key Terms

American Depositary Shares (ADSs), minimum bid price requirement, continued listing requirement, The Nasdaq Capital Market

4 terms

American Depositary Shares (ADSs) financial

"each representing 10,000 of the Company’s ordinary shares"

A U.S.-listed certificate that stands for a specific number of shares in a non‑U.S. company held by a U.S. bank, making the foreign stock tradable on American exchanges in dollars. Think of it like a local voucher that represents ownership of an overseas product — it lets U.S. investors buy and sell foreign companies without handling foreign currency or foreign brokerage accounts, but it can affect dividends, voting rights, fees, liquidity and exposure to currency and regulatory differences.

minimum bid price requirement regulatory

"minimum bid price requirement of $1.00 per share"

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

continued listing requirement regulatory

"continued listing requirement for market value of publicly held shares"

Rules a stock exchange sets that a publicly traded company must follow to keep its shares listed, such as minimum share price, market value, shareholder equity, and timely financial reporting. These rules matter to investors because failing them can lead to removal from the exchange, which can make shares harder to buy or sell and often lowers their value — like a club with membership requirements where losing eligibility restricts access and signals trouble.

The Nasdaq Capital Market regulatory

"trade on The Nasdaq Capital Market under the symbol"

A tier of the Nasdaq stock exchange that hosts smaller or early-stage public companies that meet defined listing standards for size, share price and governance. Think of it as a particular shelf in a store for emerging brands: it gives investors a centralized place to find and trade these stocks while signaling that the companies meet basic regulatory and financial rules. Investors watch it for growth opportunities and higher volatility compared with larger markets.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is RDHL’s deadline to regain Nasdaq’s minimum bid-price compliance?

Nasdaq granted RedHill an additional 180 calendar day period, through April 5, 2027, to regain compliance with the $1.00 per-share minimum bid-price requirement.

How can RDHL regain Nasdaq bid-price compliance?

If, before April 5, 2027, the closing bid price of RedHill’s ADSs is at least $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation of compliance and close the matter.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/07/2026 - 08:00 AM Accepted by SEC EDGAR 10/07/2026 - 08:00 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of October 2026
Commission File No.:001-35773

REDHILL BIOPHARMA LTD.

(Translation of registrant’s name into English)

21 Ha’arba’a Street, Tel Aviv, 6473921, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.  

Form 20-F ☒        Form 40-F ☐

RedHill Biopharma Ltd. (the “Company”) announced today that on October 6, 2026 it received a letter (the “Notification Letter”) from the Listings Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has been granted an additional 180 calendar day period, or until April 5, 2027, to regain compliance with the minimum bid price requirement of $1.00 per share set forth in Nasdaq Listing Rule 5550(a)(2).

As previously disclosed, on April 8, 2026, the Company received notification from Nasdaq indicating that, for the prior 30 consecutive business days, the closing bid price of the American Depositary Shares (“ADSs”), each representing 10,000 of the Company’s ordinary shares, had been below the minimum $1.00 per share requirement. The Company was initially provided 180 calendar days, or until October 5, 2026, to regain compliance. Except for the minimum bid requirement, the Company meets the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on The Nasdaq Capital Market.

If at any time before April 5, 2027, the closing bid price of the ADSs is at least $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide the Company with written confirmation of compliance, and the matter will be closed. The Company intends to continue to monitor the closing bid price of its ADSs and, if needed, consider available options to regain compliance prior to the expiration of the additional compliance period.

The notification has no immediate effect on the listing or trading of the ADSs, which will continue to trade on The Nasdaq Capital Market under the symbol “RDHL”.

This Form 6-K is hereby incorporated by reference into the Company's Registration Statements on Form S-8 filed with the Securities and Exchange Commission on May 2, 2013 (Registration No. 333-188286), on October 29, 2015 (Registration No. 333-207654), on July 25, 2017 (Registration No. 333-219441), on May 23, 2018 (Registration No. 333-225122), on July 24, 2019 (File No. 333-232776), on March 25, 2021 (File No. 333-254692), on May 3, 2021 (File No. 333-255710), on January 11, 2022 (File No. 333-262099), on June 27, 2022 (File No. 333-265845), on June 29, 2023 (File No. 333-273001), on June 20, 2024 (File No. 333-280327), on March 25, 2025 (File No. 333-286082) and on January 22, 2026 (File No. 333-292879), and its Registration Statements on Form F-3 filed with the Securities and Exchange Commission on March 30, 2021 (File No. 333-254848), on August 4, 2023 (File No. 333-273709), October 13, 2023 (File No. 333-274957), as amended, on August 9, 2024 (File No. 333-281417) and on July 2, 2026 (File No. 333-297223).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	REDHILL BIOPHARMA LTD.
	(the “Registrant”)
Date: October 7, 2026	By:	/s/ Dror Ben-Asher
	Name:	Dror Ben-Asher
	Title:	Chief Executive Officer